Laekna, Inc. ((HK:2105)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Laekna, Inc. is conducting a clinical study titled A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies. The study aims to assess the effectiveness and safety of combining afuresertib with fulvestrant in patients who have not responded to previous treatments, highlighting its potential significance in offering new hope for this patient group.
Intervention/Treatment: The study tests the combination of two drugs: afuresertib, an oral medication, and fulvestrant, an injectable drug. This combination is intended to treat HR+/HER2- breast cancer in patients who have exhausted other treatment options.
Study Design: The study is interventional, with a randomized, parallel assignment model. It includes both open-label and double-blind phases, ensuring comprehensive evaluation. The primary goal is treatment, with a quadruple masking approach to maintain objectivity among participants, care providers, investigators, and outcome assessors.
Study Timeline: The study began on April 13, 2021, and is currently recruiting. The last update was submitted on September 10, 2025. These dates are crucial as they indicate the study’s progression and current status, which is vital for stakeholders tracking its development.
Market Implications: This study update could positively influence Laekna, Inc.’s stock performance by showcasing their commitment to innovative cancer treatments. Successful results may enhance investor confidence and position the company favorably against competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.